DUBLIN – Immatics AG raised $58 million in a series E round that brought in Amgen Inc. as a new investor. The financing, among the top three private equity rounds closed this year by a European biotech, is confirmation that the Tuebingen, Germany-based company remains at the front rank of Europe’s immuno-oncology firms.